Targeting the mammalian target of rapamycin by everolimus is a successful approach for renal cell carcinoma (RCC) therapy. The Toll-like receptor 9 agonist immune modulatory oligonucleotide (IMO) exhibits direct antitumour and antiangiogenic activity and cooperates with both epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) inhibitors. We tested the combination of IMO and everolimus on models of human RCC with different Von-Hippel Lindau (Both IMO and everolimus inhibitedA combined treatment with everolimus and IMO is effective in